Protagen, an in-vitro diagnostics and GMP-compliant protein analysis company and Bayer Schering Pharma have closed a cooperation contract for discovery of biomarkers in Endometriosis.

Protagen and Bayer Schering Pharma aim to evaluate the UNIarray technology for discovery of autoantibody patterns for the predictive diagnosis of endometriosis.

Peter Schulz-Knappe, CSO and executive vice president of diagnostics at Protagen, said: “Biopharmaceutical companies benefit from our UNIarray approach, a proprietary technology platform with the goal to develop diagnostics based on indication-specific autoantibody patterns in blood samples from patients.

“Indication specific autoantibody patterns are not only present in classical autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals.”